INS 365
| Title | Journal |
|---|---|
| Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. | Ophthalmology 20121001 |
| Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. | Eye (London, England) 20121001 |
| Diquafosol ophthalmic solution for dry eye treatment. | Advances in therapy 20120701 |
| Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor. | Journal of medicinal chemistry 20110623 |
| Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors. | Journal of medicinal chemistry 20110428 |
| Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3. | Pulmonary pharmacology & therapeutics 20080801 |
| [A molecular marker for dry eye]. | Archivos de la Sociedad Espanola de Oftalmologia 20070301 |
| Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. | Cornea 20041101 |
| Diquafosol tetrasodium: a novel dry eye therapy. | Expert opinion on investigational drugs 20040101 |
| Diquafosol elicits increases in net Cl- transport through P2Y2 receptor stimulation in rabbit conjunctiva. | Ophthalmic research 20040101 |
| Diquafosol tetrasodium. Inspire/Allergan/Santen. | Current opinion in investigational drugs (London, England : 2000) 20031101 |
| Molecule of the month. Diquafosol tetrasodium. | Drug news & perspectives 20031001 |
| Selective P2Y2 receptor agonists stimulate vaginal moisture in ovariectomized rabbits. | Fertility and sterility 20030201 |
| Diquafosol: DE 089, diquafosol tetrasodium, INS 365, INS 365 Ophthalmic, INS 365 Respiratory, KPY 998. | Drugs in R&D 20030101 |
| Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease. | Advanced drug delivery reviews 20021205 |
| Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis. | The Journal of pharmacology and experimental therapeutics 20020901 |
| INS365 suppresses loss of corneal epithelial integrity by secretion of mucin-like glycoprotein in a rabbit short-term dry eye model. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20020801 |
| P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearance. | Chest 20020501 |
| Novel noninvasive sensitive determination of tear volume changes in normal cats. | Ophthalmic research 20020101 |
| Metabolism and transport of purinergic receptor agonists in rabbit conjunctival epithelial cells. | Advances in experimental medicine and biology 20020101 |
| Potency and duration of action of synthetic P2Y2 receptor agonists on Schirmer scores in rabbits. | Advances in experimental medicine and biology 20020101 |
| Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease. | Advances in experimental medicine and biology 20020101 |
| Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. | Pediatric pulmonology 20010801 |
| Ocular safety of INS365 ophthalmic solution: a P2Y(2) agonist in healthy subjects. | Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20010401 |
| Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. | Investigative ophthalmology & visual science 20010101 |
| The medicinal chemistry of the P2 receptor family. | Progress in medicinal chemistry 20010101 |